Similarly, secondary EGFR mutations in the outer structural domain S492R lead to cetuximab resistance by preventing EGFR antibodies from binding to their target sites in colon cancer (Montagut et al., 2012) (Figure 1). This evidence concerns the gene EGFR and colonic neoplasm.